Metabolic response as assessed by 18F ‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

ConclusionBased on these data, FDG ‐PET does not appear to predict EFS in IR or HR‐RMS. It remains to be determined whether FDG‐PET has a role in predicting survival outcomes in other RMS subpopulations.

Source: Cancer Medicine - December 19, 2020 Category: Cancer & Oncology Authors: Douglas J. Harrison, Yueh ‐Yun Chi, Jing Tian, Pooja Hingorani, Leo Mascarenhas, Geoffrey B. McCowage, Brenda J. Weigel, Rajkumar Venkatramani, Suzanne L. Wolden, Torunn I. Yock, David A. Rodeberg, Andrea A. Hayes‐Jordan, Lisa A. Teot, Sh Tags: ORIGINAL RESEARCH Source Type: research